293.16MMarket Cap-2.27P/E (TTM)
7.610High6.980Low84.37KVolume7.020Open7.005Pre Close595.11KTurnover0.72%Turnover RatioLossP/E (Static)41.79MShares26.25152wk High0.82P/B82.50MFloat Cap5.83052wk Low--Dividend TTM11.76MShs Float26.251Historical High--Div YieldTTM8.99%Amplitude5.830Historical Low7.053Avg Price1Lot Size
Zenas BioPharma Stock Forum
Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases
Wednesday, 5th February at 7:05 am
- Advancing Phase 2 and Phase 3 trials of obexelimab, a unique CD-19 x FcγRIIb inhibitor of B cell function-
-Topline results from Phase 2 Trial in Relapsing Multiple Sclerosis (MoonStone) expected in third quarter 2025-
-Topline results from pivotal Phase 3 Tr...
No comment yet